Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Wearable Core Body Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Outpatients Receiving CAR T-Cell Therapy

2. November 2026 aktualisiert von: Wake Forest University Health Sciences

A Randomized Controlled Trial of a Wearable Core Body Temperature Sensor Versus Standard Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Patients Undergoing CAR T-Cell Therapy in an Outpatient Setting

The purpose of this research study is to see if a wearable temperature monitoring patch can detect cytokine release syndrome earlier than traditional oral temperature monitoring.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This randomized pilot study is designed to evaluate the efficacy of a continuous temperature-monitoring wearable patch in patients receiving CAR-T therapy in the outpatient setting, comparing its performance to standard institutional monitoring protocols.

Studientyp

Interventionell

Einschreibung (Geschätzt)

105

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

Studienorte

    • North Carolina
      • Charlotte, North Carolina, Vereinigte Staaten, 28204
      • Winston-Salem, North Carolina, Vereinigte Staaten, 27103
        • Atrium Health Wake Forest Baptist Comprehensive Cancer Center
        • Kontakt:

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

Patients:

  1. Ability to understand and willingness to sign an IRB-approved informed consent
  2. Age ≥ 18 years at the time of consent
  3. Scheduled to undergo CAR-T therapy in the outpatient setting at AHWFBCCC
  4. Ability to read and understand the English and/or Spanish language
  5. As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study
  6. Access to a mobile device for the duration of the trial

Provider/Staff:

Provider/staff participants must meet all of the following inclusion criteria to participate in the study:

  1. Verbally agree to participate
  2. Hospital at Home outpatient provider/advanced practice provider/nurse of at least one patient participant enrolled on Arm A who completed 14 days of temperature monitoring

Exclusion Criteria:

Patients:

  1. Planned prophylactic tocilizumab for mitigation of CRS as documented in the clinical trials pathway submission
  2. History of silicone allergy
  3. History of Medical Adhesive-Related Skin Injury (MARSI)
  4. Known skin condition that might preclude safe application of the patch, in the opinion of the enrolling investigator

Provider/Staff:

None

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Unterstützende Pflege
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Sonstiges: Arm A: TempShield Continuous Temperature Monitoring plus SOC Temperature Monitoring

Standard of care oral temperature monitoring plus TempShield continuous temperature monitoring patch

Patient participants will receive instruction from a research designee regarding use of the TempShield patch and smartphone application for continuous at-home temperature monitoring. Patient participants will complete onboarding of the application on their smartphone with assistance from the research designee, if necessary. Patient participants should place the patch immediately after completion of CAR-T infusion in the outpatient setting, with assistance from the research designee.

Sonstiges: Arm B: SOC Temperature Monitoring

Standard of care oral temperature monitoring

Standard of care oral temperature monitoring

Kein Eingriff: Arm C: Provider/Staff

Providers/staff are Hospital at Home personnel who support patients undergoing outpatient CAR-T therapy and who have monitored at least one participant enrolled on Arm A of the study.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Time to first recorded temperature elevation indicative of Cytokine Release Syndrome (CRS)
Zeitfenster: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Time (in hours) from the initiation of CAR-T infusion to the first occurrence of a recorded body temperature elevation of ≥ 100.4°F (38.0°C) during the 14-day post-CAR-T observation period. Participants who do not experience this defined temperature elevation within the 14 days will be censored at the time of their last recorded temperature reading during this window. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Incidence of temperature elevation indicative of Cytokine Release Syndrome (CRS)
Zeitfenster: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants who experience at least one recorded body temperature elevation of ≥ 100.4°F (38.0°C) during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Incidence of high-grade (grade 2 or higher) Cytokine Release Syndrome (CRS)
Zeitfenster: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants who experience grade 2 or higher CRS during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Time to resolution of Cytokine Release Syndrome (CRS) from temper elevation indicative of CRS (temperature ≥ 100.4 °F)
Zeitfenster: From the temperature elevation (≥ 100.4 °F) to resolution during the 14 days after CAR-T infusion.

Time (in hours) from the from onset of fever indicative of CRS (temperature ≥ 100.4 °F) during the 14-day post-CAR-T observation period to resolution (i.e., when the participant no longer meets the CRS diagnostic criteria). If a participant experiences multiple episodes of CRS during the 14-day post-CAR-T observation period, the duration can be calculated per episode and cumulatively. This will be calculated for participants experiencing CRS (temperature ≥ 100.4 °F) during the 14-day post-CAR-T observation period. Reported by arm.

From the temperature elevation (≥ 100.4 °F) to resolution during the 14 days after CAR-T infusion.
Time to intervention after fever detection (temperature ≥ 100.4 °F)
Zeitfenster: From the temperature elevation (≥ 100.4 °F) to intervention during the 14 days after CAR-T infusion.

Time (in hours) from documented temperature elevation of ≥ 100.4° F to clinician intervention (e.g., supportive care, medication followed by observation, etc.). This will be calculated for participants experiencing CRS during the 14-day post-CAR-T observation period. Reported by arm.

From the temperature elevation (≥ 100.4 °F) to intervention during the 14 days after CAR-T infusion.
Incidence of admission to the Intensive Care Unit (ICU) due to temperature elevation indicative of CRS
Zeitfenster: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants admitted to the ICU due to temperature elevation indicative of CRS during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Time to discharge after admission to the Intensive Care Unit (ICU)
Zeitfenster: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Time (in hours) from ICU admission to ICU discharge. If a participant has multiple ICU admissions during the 14-day post-CAR-T observation period, the duration will be calculated cumulatively. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Length of hospital stay
Zeitfenster: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of inpatient nights from hospital admission to hospital discharge due to temperature elevation indicative of CRS during the 14-day post-CAR-T observation period. If a participant has multiple hospital admissions due to CRS during the 14-day post-CAR-T observation period, the duration reported will be cumulative across all stays. This endpoint will be calculated for participants admitted to this hospital during the 14-day post-CAR-T observation period due to temperature elevation indicative of CRS. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Incidence of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Zeitfenster: From the initiation of CAR-T infusion up to Day 14 post-infusion.

Number of participants experiencing ICANS during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Largest change in body temperature from baseline recorded during the 14-day post-CAR-T observation period
Zeitfenster: From the initiation of CAR-T infusion up to Day 14 post-infusion.

The maximum numerical difference in body temperature recorded from baseline during the 14-day post-CAR-T observation period. Reported by arm.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
The proportion of hours during the 14-day post CAR-T observation period when patch was worn
Zeitfenster: From the initiation of CAR-T infusion up to Day 14 post-infusion.

The proportion of hours during the 14-day post-CAR-T observation period in which at least one valid human body temperature reading (86 °F to 108 °F) was recorded by the wearable patch, defined as Total adherence = (Number of hours with at least one valid temperature reading)/(24*14 hours). This will be calculated for participants randomized to wear the remote temperature monitoring device.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
The proportion of paired temperature readings from the temperature patch and an oral thermometer within one degree Fahrenheit in a five-minute window during the 14-day post-CAR-T observation period
Zeitfenster: From the initiation of CAR-T infusion up to Day 14 post-infusion.

The number 5-minute intervals in the 14-day post-CAR-T observation period (from the first patch reading indicating a temperature from 86 °F to 108 °F), when concordance between the temperature patch and an oral thermometer within one degree Fahrenheit was observed.

From the initiation of CAR-T infusion up to Day 14 post-infusion.
Patient satisfaction with CAR-T temperature monitoring methods
Zeitfenster: The Day 14 post-infusion (+28 days) study calendar visit.

Patient satisfaction as assessed by the study survey, evaluating satisfaction on a Likert scale where higher scores indicate a higher level of patient satisfaction with the assigned monitoring method (standard of care vs. wearable patch).

The Day 14 post-infusion (+28 days) study calendar visit.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Mitarbeiter

Ermittler

  • Hauptermittler: Cindy Varga, MD, Wake Forest University Health Sciences

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

1. Dezember 2026

Primärer Abschluss (Geschätzt)

1. August 2028

Studienabschluss (Geschätzt)

2. Januar 2029

Studienanmeldedaten

Zuerst eingereicht

26. Oktober 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

26. Oktober 2026

Zuerst gepostet (Tatsächlich)

2. November 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

5. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

2. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • IRB00158734
  • ONC-MM-2501 (Andere Kennung: Atrium Health Wake Forest Baptist Comprehensive Cancer Center)

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .